Bryostatin 1 In Treating Patients With Progressive Kidney Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of bryostatin 1 in treating patients who have progressive kidney cancer
|Study Design:||Primary Purpose: Treatment|
|Official Title:||A Phase II Trial of Bryostatin-1 in Hypernephroma|
|Study Start Date:||March 1999|
|Study Completion Date:||July 2006|
OBJECTIVES: I. Determine the response rates in patients with progressive hypernephroma treated with bryostatin 1. II. Determine the toxicity of this regimen in these patients.
OUTLINE: This is a multicenter study. Patients receive bryostatin 1 IV over 24 hours on days 1, 8, and 15. Treatment repeats every 4 weeks for 2 courses. For patients with stable or responding disease after completion of course 2, treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: A total of 14-25 patients will be accrued for this study within 12-18 months.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00005056
|Oxford Radcliffe Hospital|
|Oxford, England, United Kingdom, 0X3 7LJ|
|Imperial Cancer Research Fund Medical Oncology Unit|
|Oxford, England, United Kingdom, OX3 7LJ|
|Study Chair:||Adrian L. Harris, MD||Oxford University Hospitals NHS Trust|